Overview

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, double-blind, placebo-controlled study in patients with stable heart failure to evaluate the safety, tolerability, pharmacokinetics, and efficacy of multiple ascending doses of Bendavia™ (MTP-131) intravenous infusion.
Phase:
Phase 1
Details
Lead Sponsor:
Stealth BioTherapeutics Inc.